A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis

• Status: RECRUITING
• Trial end date: 2025-12-01

Summary

This trial was designed to evaluate the safety of SHR-1819 in children and adolescents with moderate-to-severe atopic dermatitis.

• Phase: PHASE1

Details

• Lead Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd